Market capitalization | $0.00 |
Enterprise Value | $-2.58m |
P/E (TTM) P/E ratio | 0.00 |
P/B ratio (TTM) P/B ratio | 0.00 |
EBIT (operating result TTM) EBIT | $-15.80m |
Short interest | 0.78% |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
2 Analysts have issued a ObsEva SA forecast:
2 Analysts have issued a ObsEva SA forecast:
Jun '23 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -16 -16 |
75%
75%
|
Net Profit | - - |
-
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ObsEva SA engages in the research and development of therapeutic treatments for woman's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet in November 2012 and is headquartered in Geneva, Switzerland.
Head office | Switzerland |
CEO | Fabien Ladonchamps |
Employees | 15 |
Founded | 2012 |
Website | www.obseva.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.